| GC16698-5mg |
|
1421373-66-1 |
|
0 |
C29H37N7O5S |
|
|
|
| GC16697-50mg |
|
1181681-43-5 |
|
0 |
C21H24ClFO5 |
|
|
|
| GC16697-10mg |
|
1181681-43-5 |
|
0 |
C21H24ClFO5 |
|
|
|
| GC16697-5mg |
|
1181681-43-5 |
|
0 |
C21H24ClFO5 |
|
|
|
| GC16697-1mg |
|
1181681-43-5 |
|
0 |
C21H24ClFO5 |
|
|
|
| GC16696-10mM (in 1mL DMSO) |
|
1 |
Dibucaine (Cinchocaine) HCl
|
0 |
C20H29N3O2.HCl |
|
|
|
| GC16696-10mg |
|
1 |
Dibucaine (Cinchocaine) HCl
|
0 |
C20H29N3O2.HCl |
|
|
|
| GC16695-1mg |
|
1315378-74-5 |
Bax inhibitor peptide, negative control
|
0 |
C28H52N6O6S |
|
|
|
| GC16694-10mM (in 1mL DMSO) |
|
761439-42-3 |
|
0 |
C30H40ClN7O3S |
|
|
|
| GC16694-100mg |
|
761439-42-3 |
|
0 |
C30H40ClN7O3S |
|
|
|
| GC16694-50mg |
|
761439-42-3 |
|
0 |
C30H40ClN7O3S |
|
|
|
| GC16694-10mg |
|
761439-42-3 |
|
0 |
C30H40ClN7O3S |
|
|
|
| GC16694-5mg |
|
761439-42-3 |
|
0 |
C30H40ClN7O3S |
|
|
|
| GC16693-10mg |
|
17735-98-7 |
13Z,16Z-Docosadienoic Acid
|
0 |
C22H40O2 |
|
|
|
| GC16693-5mg |
|
17735-98-7 |
13Z,16Z-Docosadienoic Acid
|
0 |
C22H40O2 |
|
|
|
| GC16693-1mg |
|
17735-98-7 |
13Z,16Z-Docosadienoic Acid
|
0 |
C22H40O2 |
|
|
|
| GC16692-50mg |
|
425399-05-9 |
|
0 |
C20H22N2O |
|
|
|
| GC16692-10mg |
|
425399-05-9 |
|
0 |
C20H22N2O |
|
|
|
| GC16692-5mg |
|
425399-05-9 |
|
0 |
C20H22N2O |
|
|
|
| GC16691-10mM (in 1mL DMSO) |
|
80-77-3 |
|
0 |
C11H12ClNO3S |
|
|
|
